Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AIXC

AIxCrypto Holdings Inc

Feb 06 • 04:00PM ET

1.42

+0.05 3.65 %

Technology • Software - Infrastructure • USA • NASD

Peers: MRNA BNTX NVAX INO CERS VXRT ALT AIM PDSB ADMA

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-8.66	Insider Own	6.19%	Shs Outstand	5.16M	Perf Week	-19.77%
Market Cap	7.33M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.84M	Perf Month	-47.21%
Enterprise Value	7.89M	PEG	-	EPS next Q	-	Inst Own	0.67%	Short Float	1.95%	Perf Quarter	-46.01%
Income	-8.09M	P/S	-	EPS this Y	-	Inst Trans	7.18%	Short Ratio	0.74	Perf Half Y	-23.24%
Sales	0.00M	P/B	1.77	EPS next Y	-	ROA	-31.56%	Short Interest	0.09M	Perf YTD	-39.32%
Book/sh	0.80	P/C	0.19	EPS next 5Y	-	ROE	-39.69%	52W High	8.81 -83.88%	Perf Year	-56.97%
Cash/sh	7.51	P/FCF	-	EPS past 3/5Y	61.60% 79.32%	ROIC	-21.00%	52W Low	1.36 4.41%	Perf 3Y	-98.01%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.88% 8.28%	Perf 5Y	-99.92%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	84.34%	Oper. Margin	-	ATR (14)	0.19	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	8.83	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	26.45	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.83	EPS Q/Q	0.33%	SMA20	-31.83%	Beta	0.37	Target Price	250.00
Payout	-	Debt/Eq	0.08	Sales Q/Q	-	SMA50	-39.87%	Rel Volume	0.52	Prev Close	1.37
Employees	-	LT Debt/Eq	0.00	Earnings	-	SMA200	-52.52%	Avg Volume	127.66K	Price	1.42
IPO	Jun 24, 2015	Option/Short	No / Yes	EPS/Sales Surpr.	21.74% -100.00%	Trades		Volume	66,101	Change	3.65%

Feb-05-26 01:59AM	AIxCrypto and FF AI-Robotics Announce Strategic Partnership to Explore Web3 Infrastructure for Embodied AI (PR Newswire) -15.43%
Feb-03-26 11:30AM	AIxCrypto, Sei Development Foundation announce collaboration (TipRanks) +6.40%
11:30AM	AIxCrypto says AIxC Hub surpasses 1M registered wallets (TipRanks)
Feb-02-26 11:21AM	AIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: $10 million FFAI Strategic Investment, 1M+ Wallets, and Sei Collaboration (PR Newswire)
11:21AM	AIxC and Sei Development Foundation Announce Strategic Collaboration (PR Newswire)
03:01PM	Loading…
Jan-28-26 03:01PM	AIxCrypto Inc. Surpasses 1.1 Million Registered Wallets as AIxC Hub Launches "Tenki" Interactive Game (PR Newswire)
Jan-23-26 12:24AM	AIXC Continues Strategic Corporate Expansion to Support Hyper-Growth of AIxC Hub Ecosystem (PR Newswire)
Jan-15-26 08:54PM	AIxC Announces AIxC Hub Exceeds 500,000 Registered Wallets in First Week Following Launch (PR Newswire) -5.98%
Jan-12-26 02:47AM	AIxCrypto Launches AIxC Hub Ecosystem Platform; Inaugural S1 Arena Attracts Over 200,000 Participants in Five Days (PR Newswire) +5.08%
Jan-06-26 01:39PM	AIxC to Advance Tokenization Strategy with Proposed Strategic Investment in Faraday Future (PR Newswire)
Dec-23-25 09:00AM	AIxCrypto Establishes UAE Subsidiary and Obtains Web3 Operations License Approval to Support Global AI and Web3 Expansion (PR Newswire)
Dec-17-25 01:01AM	AIxC Appoints Andrew Grossman As Head of Legal Where He Will Direct the Company's Legal, Compliance, and Governance Strategy (PR Newswire) +6.74%
Dec-14-25 11:44PM	YT Jia, Chief Advisor to AIxC Shares Weekly AIxC Investor Update: AIxC Appointed Andrew Grossman as Head of Legal Where he will Take Full Responsibility for the Company's Legal, Compliance, and Governance Framework (PR Newswire)
Nov-20-25 12:36PM	AIxCrypto Rebrands and Begins Trading Under New Ticker AIXC, Advancing Its "Three Driving Forces" Strategy to Become the No.1 Gateway to AI Web3 and a Bridge Between Web2 and Web3 (PR Newswire) -8.68%
Nov-16-25 04:10PM	Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI x Web3 Strategy (GlobeNewswire)
11:57PM	Loading…
Oct-27-25 11:57PM	Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025 (GlobeNewswire) -18.41% -7.41%
Oct-23-25 04:05PM	Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation (GlobeNewswire) +5.37%
Oct-12-25 09:00PM	Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For? (GlobeNewswire)
Oct-06-25 07:00PM	Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition (GlobeNewswire)
Sep-30-25 07:08AM	Qualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into Crypto (GlobeNewswire) +6.32%
Sep-23-25 10:00AM	This Penny Stock Is Surging Big Time on a Tie-Up With Faraday Future and a Push Into Crypto. Should You Buy Its Shares Here? (Barchart) -25.32%
Sep-19-25 06:01PM	Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction (GlobeNewswire) +94.72%
Jul-28-25 05:20PM	Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing Status (GlobeNewswire) -10.00%
12:41PM	Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock (GlobeNewswire)
Jul-16-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +11.33%
08:00AM	Qualigen Granted New Patents Covering 25 Countries (GlobeNewswire)
May-19-25 05:25PM	Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q (GlobeNewswire)
May-01-25 04:20PM	Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K (GlobeNewswire)
Apr-01-25 08:00AM	Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme (GlobeNewswire)
Jan-28-25 08:00AM	Qualigen to participate in next funding round for NanoSynex (GlobeNewswire) -21.42%
09:00AM	Loading…
Dec-05-24 09:00AM	Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement (GlobeNewswire)
Nov-25-24 05:00PM	Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (GlobeNewswire) -6.50%
Nov-19-24 09:00AM	Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares (GlobeNewswire) +6.04%
Nov-01-24 09:00AM	Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 (GlobeNewswire)
Sep-26-24 05:10PM	Qualigen Therapeutics, Inc. Announces management changes. (GlobeNewswire)
Sep-20-24 09:00AM	Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel (GlobeNewswire)
Sep-06-24 05:00PM	Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (GlobeNewswire)
04:30PM	Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering (GlobeNewswire)
Sep-05-24 09:00AM	Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering (GlobeNewswire) -10.68%
Aug-16-24 09:53PM	QLGN Stock Earnings: Qualigen Therapeutics Reported Results for Q2 2024 (InvestorPlace) +11.48%
Jul-15-24 08:19AM	Why Is Qualigen Therapeutics (QLGN) Stock Down 22% Today? (InvestorPlace) -10.92%
07:35AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jul-12-24 11:56AM	Mizuho Just Raised Its Price Target on Tesla (TSLA) Stock (InvestorPlace) +111.45%
11:15AM	Why Is Qualigen (QLGN) Stock Up 141% Today? (InvestorPlace)
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jul-09-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) -20.79%
Jul-08-24 10:08AM	Boeing Pleads Guilty: Why BA Stock Is Up on Criminal Case News (InvestorPlace)
08:35AM	Why Is Qualigen Therapeutics (QLGN) Stock Down 12% Today? (InvestorPlace)
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jul-02-24 09:52PM	QLGN Stock Earnings: Qualigen Therapeutics Reported Results for Q1 2024 (InvestorPlace) +5.98%
Jul-01-24 08:00AM	Lifecore Biomedical Announces Cooperation Agreement with 22NW (GlobeNewswire)
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +18.58%
Jun-20-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -5.29%
Jun-03-24 10:53AM	QLGN Stock Earnings: Qualigen Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
May-30-24 04:00PM	Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination (GlobeNewswire)
Apr-16-24 07:00AM	Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft (GlobeNewswire) -6.28%
Apr-10-24 08:00AM	Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Apr-09-24 08:00AM	Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Nov-14-23 04:30PM	Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 (GlobeNewswire)
Nov-07-23 08:30AM	Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors (GlobeNewswire)
Oct-23-23 08:30AM	Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer (GlobeNewswire)
Sep-27-23 08:30AM	Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023 (GlobeNewswire)
Aug-30-23 07:09AM	QLGN: Receives U.S. FDA IND Clearance; Phase 1 Trial to Initiate 2H23 (Zacks)
Aug-17-23 08:30AM	Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors (GlobeNewswire)
Aug-15-23 08:30AM	Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023 (GlobeNewswire)
Aug-01-23 08:30AM	Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors (GlobeNewswire)
Jul-24-23 08:15AM	Qualigen Therapeutics Divests FastPack® Diagnostics Business (GlobeNewswire)
Jun-14-23 10:30AM	QLGN: Data for Pan-RAS Platform Presented at ASCO (Zacks Small Cap Research)
Jun-05-23 08:15AM	Poster Highlighting Qualigen Therapeutics Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire)
May-16-23 08:00AM	Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023 (GlobeNewswire)
May-12-23 07:20AM	QLGN: IND for QN-302 to be Submitted in Mid-2023 (Zacks Small Cap Research) -5.69%
May-02-23 04:30PM	Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +7.29% -5.98%
08:15AM	Qualigen Therapeutics Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire)
Apr-21-23 05:46PM	Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing (GlobeNewswire)
Apr-18-23 08:45AM	Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL (GlobeNewswire) -5.48%
07:30AM	Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL (GlobeNewswire)
Mar-21-23 08:35AM	Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office (GlobeNewswire) +16.33%
Mar-15-23 09:05AM	Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-09-23 08:30AM	Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference (GlobeNewswire)
Mar-08-23 08:05AM	Data on Potential Biomarker for Qualigen Therapeutics Lead Program QN-302 Published in Peer-Reviewed Journal Molecules (GlobeNewswire) -7.14%
Feb-01-23 09:05AM	Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders (GlobeNewswire) +10.85%
Jan-24-23 09:00AM	Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302 (GlobeNewswire)
Jan-23-23 09:02AM	Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications (GlobeNewswire)
Jan-10-23 09:00AM	Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer (GlobeNewswire) +5.51%
Jan-05-23 09:00AM	Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform (GlobeNewswire) +9.73%
Dec-12-22 08:30AM	Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire)
Dec-07-22 09:10AM	Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors (GlobeNewswire) -6.21%
Dec-01-22 07:11AM	QLGN: Encouraging Preclinical Data Presented for QN-302 and RAS Inhibitor (Zacks Small Cap Research) +20.20%
Nov-22-22 09:00AM	Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split (GlobeNewswire) -14.50%
Nov-17-22 06:12AM	Qualigen Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-15-22 07:30AM	Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-19-22 09:00AM	Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute (GlobeNewswire)
Oct-18-22 09:00AM	Qualigen Therapeutics to Present at LD Micro Main Event XV (GlobeNewswire)
Oct-06-22 08:00AM	Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium (GlobeNewswire) -10.06%
Sep-14-22 05:02PM	Qualigen Therapeutics Presents Data on QN-302 at AACRs Pancreatic Cancer Meeting (GlobeNewswire) -5.71%
Aug-25-22 06:45AM	QLGN: FastPack Sales Up 28% YoY (Zacks Small Cap Research)
Aug-18-22 09:15AM	Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board (GlobeNewswire)
Aug-16-22 07:30AM	Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-01-22 08:30AM	Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model (GlobeNewswire)
Jul-06-22 09:00AM	Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302 (GlobeNewswire)

AIxCrypto Holdings, Inc. is dedicated to building an ecosystem that integrates AI and blockchain while bridging Web2 and Web3. Its core products include the BesTrade DeAI Agent and the AIxC ecosystem products. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AIXC

AIxCrypto Holdings Inc

Upgrade your FINVIZ experience